Clinical Trial Update: A Phase 2b Study of SPI-1005 to Prevent Acute Noise Induced Hearing Loss [Phase 2]

View source ↗

Summary

Phase 2b study update for SPI-1005 aimed at preventing acute noise-induced hearing loss; current status unavailable.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Noise-induced Hearing Loss

Drugs mentioned

• SPI-1005

Snippet

Sponsor: Sound Pharmaceuticals, Incorporated | Conditions: Noise Induced Hearing Loss | Phase 2 | Status: UNKNOWN